Menu
Enrolling by invitation NCT07660640

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

— Observational Age-Related Macular Degeneration (AMD) Non-Neovascular Age-Related Macular Degeneration

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: observational study, VOY-101.
Who it may be relevant to
Registry conditions: Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration. Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Israel
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study

Overview

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Detailed description

This is a long-term observational, non-interventional extension study to the Phase 1/2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).

Interventions

  • Other observational study
    No intervention - observational study
  • Biological VOY-101
    One-time intravitreal injection of VOY-101.

Primary outcome measures

  • Frequency of ocular and systemic VOY-101 related AEs [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

  • Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101.
  • Are willing and able to understand and provide informed consent.

Exclusion criteria

There are no exclusion criteria for this study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

United States · 3 centers
  • Ophthalmic Consultants of Boston — Boston
  • Retina Consultants of Texas — Bellaire
  • University of Utah — Salt Lake City
Israel · 1 center
  • Sourasky Medical Center - Ichilov — Tel Aviv

Identifiers

NCT: NCT07660640 · PBI-AMD-901

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗